Prevention of acute and chronic allograft rejection with CD4 +CD25+Foxp3+ regulatory T lymphocytes

Nature Medicine

Volumn 14, Issue 1, 2008, Pages 88-92

  Joffre, Olivier ^a,b,d   Santolaria, Thibault ^a,b   Calise, Denis ^a   Saati, Talal Al ^a   Hudrisier, Denis ^a,b,e   Romagnoli, Paola ^a,b   Van Meerwijk, Joost P M ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN TRANSPLANTATION;

ANIMALS; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; IMMUNE TOLERANCE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISOANTIGENS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SKIN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

MUS;

EID: 38049020656     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1688     Document Type: Article

References (30)

1. Lechler, R.I., Sykes, M., Thomson, A.W. & Turka, L.A. Organ transplantation - how much of the promise has been realized? Nat. Med. 11, 605-613 (2005).
2. Waldmann, H. & Cobbold, S. Exploiting tolerance processes in transplantation. Science 305, 209-212 (2004).
3. Stockinger, B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv. Immunol. 71, 229-265 (1999).
4. + regulatory T cells. Immunol. Rev. 212, 60-73 (2006).
5. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212, 8-27 (2006).
6. Izcue, A., Coombes, J.L. & Powrie, F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol. Rev. 212, 256-271 (2006).
7. Belkaid, Y., Blank, R.B. & Suffia, I. Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol. Rev. 212, 287-300 (2006).
8. Rouse, B.T., Sarangi, P.P. & Suvas, S. Regulatory T cells in virus infections. Immunol. Rev. 212, 272-286 (2006).
9. Aluvihare, V.R., Kallikourdis, M. & Betz, A.G. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5, 266-271 (2004).
10. Beyer, M. & Schultze, J.L. Regulatory T cells in cancer. Blood 108, 804-811 (2006).
11. Joffre, O. & van Meerwijk, J.P.M. CD4+CD25+ regulatory T lymphocytes in bone marrow transplantation. Semin. Immunol. 18, 128-135 (2006).
12. + regulatory T cells. Int. Immunol. 16, 1189-1201 (2004).
13. + regulatory T cells promote experimental transplantation tolerance. Blood 109, 827-835 (2007).
14. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190 (2000).
15. Le Moine, A. et al. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J. Clin. Invest. 103, 1659-1667 (1999).
16. Rocha, P.N., Plumb, T.J., Crowley, S.D. & Coffman, T.M. Effector mechanisms in transplant rejection. Immunol. Rev. 196, 51-64 (2003).
17. + T lymphocytes. Blood 103, 4216-4221 (2004).
18. Sykes, M. Mixed chimerism and transplant tolerance. Immunity 14, 417-424 (2001).
19. Boyse, E.A., Lance, E.M., Carswell, E.A., Cooper, S. & Old, L.J. Rejection of skin allografts by radiation chimaeras: selective gene action in the specification of cell surface structure. Nature 227, 901-903 (1970).
20. Ildstad, S.T., Wren, S.M., Bluestone, J.A., Barbieri, S.A. & Sachs, D.H. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J. Exp. Med. 162, 231-244 (1985).
21. Sharabi, Y. & Sachs, D.H. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J. Exp. Med. 169, 493-502 (1989).
22. Luo, B., Chan, W.F., Shapiro, A.M. & Anderson, C.C. Non-myeloablative mixed chimerism approaches and tolerance, a split decision. Eur. J. Immunol. 37, 1233-1242 (2007).
23. Vriesendorp, H.M. Aims of conditioning. Exp. Hematol. 31, 844-854 (2003).
24. Cosimi, A.B. & Sachs, D.H. Mixed chimerism and transplantation tolerance. Transplantation 77, 943-946 (2004).
25. Fudaba, Y. et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant. 6, 2121-2133 (2006).
26. Salama, A.D., Womer, K.L. & Sayegh, M.H. Clinical transplantation tolerance: many rivers to cross. J. Immunol. 178, 5419-5423 (2007).
27. + regulatory T cells ex vivo. Blood 102, 2180-2186 (2003).
28. Gorelik, L. & Flavell, R.A. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171-181 (2000).
29. Coudert, J.D., Coureau, C. & Guery, J.C. Preventing NK cell activation by donor dendritic cells enhances allospecific CD4 T cell priming and promotes Th type 2 responses to transplantation antigens. J. Immunol. 169, 2979-2987 (2002).
30. Corry, R.J., Winn, H.J. & Russell, P.S. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 16, 343-350 (1973).